Evidence map›Paper›PMID 20338627›Full record

SynthesisLancet (London, England)2010

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

NSCLC Meta-analyses Collaborative Group, R Arriagada, A Auperin, S Burdett, J P Higgins, D H Johnson, T Le Chevalier, C Le Pechoux, M K B Parmar, J P Pignon and 6 more

5 registry-linked trialsOpen access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Lancet (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 290 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
290citing papers in PubMed, 12 pooled it
25.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02259621 phase2active not recruitingnot on this mapstarted 2014, after this paper: background citation

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.

TypeinterventionalSponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsRan2014 to 2027Enrolled39ConditionsNon-Small Cell Lung CancerArmsNivolumab, Carboplatin, Paclitaxel, Ipilimumab
NCT02716038 phase2completednot on this mapstarted 2016, after this paper: background citation

A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)

TypeinterventionalSponsorColumbia UniversityRan2016 to 2022Enrolled39ConditionsCarcinoma, Non-Small-Cell LungArmsMPDL3280A, Carboplatin, Nab-paclitaxel
NCT02974426 phase3terminatednot on this mapstarted 2016, after this paper: background citation

Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer

TypeinterventionalSponsorShanghai Chest HospitalRan2016 to 2024Enrolled132ConditionsNon-small Cell Lung Cancer Stage IIIA, RadiotherapyArmsPORT-first, PORT-last, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
NCT02977169 phase2unknown statusnot on this mapstarted 2016, after this paper: background citation

Phase II Study to Evaluate the Role of Postoperative Radiotherapy for Low Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer

TypeinterventionalSponsorShanghai Chest HospitalRan2016 to 2021Enrolled300ConditionsNon-small Cell Lung Cancer Stage IIIA, RadiotherapyArmsPORT, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
NCT06467383 recruitingnot on this mapstarted 2024, after this paper: background citation

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

TypeobservationalSponsorMSD Italia S.r.l.Ran2024 to 2025Enrolled600ConditionsNon-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
3 · Its place in the literature

Who cites it

290 citing papers in PubMed, 12 syntheses or guidelines pooled it, 627 citations in OpenAlex.

  1. Pooled it
  2. Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

230 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

NSCLC Meta-analyses Collaborative GroupMeta-analysis Group, MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK.
R Arriagada
A Auperin
S Burdett
J P Higgins
D H Johnson
T Le Chevalier
C Le Pechoux
M K B Parmar
J P Pignon
R L Souhami
R J Stephens
L A Stewart
J F Tierney
H Tribodet
J van Meerbeeck
MRC Clinical Trials Unit at UCL · GB

Funding

Cancer Research UK 11339Medical Research Council MC_U105285807Medical Research Council MC_U122861323
6 · The paper itself

Abstract

backgroundMany randomised controlled trials have investigated the effect of adjuvant chemotherapy in operable non-small-cell lung cancer. We undertook two comprehensive systematic reviews and meta-analyses to establish the effects of adding adjuvant chemotherapy to surgery, or to surgery plus radiotherapy.

methodsWe included randomised trials, not confounded by additional therapeutic differences between the two groups and that started randomisation on or after Jan 1, 1965, which compared surgery plus adjuvant chemotherapy versus surgery alone, or surgery plus adjuvant radiotherapy and chemotherapy versus surgery plus adjuvant radiotherapy. Updated individual patient data were collected, checked, and included in meta-analyses stratified by trial. The primary endpoint was overall survival, defined as time from randomisation until death by any cause. All analyses were by intention to treat.

findingsThe first meta-analysis of surgery plus chemotherapy versus surgery alone was based on 34 trial comparisons and 8447 patients (3323 deaths). We recorded a benefit of adding chemotherapy after surgery (hazard ratio [HR] 0.86, 95% CI 0.81-0.92, p<0.0001), with an absolute increase in survival of 4% (95% CI 3-6) at 5 years (from 60% to 64%). The second meta-analysis of surgery plus radiotherapy and chemotherapy versus surgery plus radiotherapy was based on 13 trial comparisons and 2660 patients (1909 deaths). We recorded a benefit of adding chemotherapy to surgery plus radiotherapy (HR 0.88, 95% CI 0.81-0.97, p=0.009), representing an absolute improvement in survival of 4% (95% CI 1-8) at 5 years (from 29% to 33%). In both meta-analyses we noted little variation in effect according to the type of chemotherapy, other trial characteristics, or patient subgroup.

interpretationThe addition of adjuvant chemotherapy after surgery for patients with operable non-small-cell lung cancer improves survival, irrespective of whether chemotherapy was adjuvant to surgery alone or adjuvant to surgery plus radiotherapy.

fundingUK Medical Research Council, Institut Gustave-Roussy, Programme Hospitalier de Recherche Clinique (AOM 05 209), Ligue Nationale Contre le Cancer, and Sanofi-Aventis.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantFemaleHumansLung NeoplasmsMaleMiddle AgedRadiotherapy, AdjuvantRandomized Controlled Trials as TopicSurvival Rate

Identifiers

PMID20338627
PMCPMC2853682
OpenAlexW1740332796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.